DIABETES represents a global health crisis, profoundly impacting the lives of 537 million people worldwide, including approximately 64 million who rely on daily insulin injections for disease management.
Insulet (NASDAQ: PODD) is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform.
The fifth generation and flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with the world’s most widely used continuous glucose monitoring sensor brands, and uses a cutting edge, model predictive control algorithm to compute personalised insulin dosages and delivery.
The company recently opened its state-of-the-art 400,000 sq ft space facility in Malaysia. Throughout the design process, the Insulet team remained dedicated to environmental sustainability by integrating pre- and post-recycled content and utilising regional materials in the building.
Insulet implemented an underground rainwater harvesting system, consisting of three capture units, reducing potential stress on local water sources by meeting 30% of the landscaping water needs.
Renewable energy has been incorporated into Insulet operations where a solar array of more than 5,700 solar panels have been installed on the roof generating 15% of power needs.
Three electric vehicle (EV) charging stations are available to promote EV usage amongst employees.
Growth at Insulet extends beyond physical infrastructure and manufacturing capacity, focusing on attracting talented, passionate individuals working towards a common purpose.
This growth is a collective effort, driven by contributions from people and teams across the 25 countries where Insulet operates.
Therefore in Malaysia, Insulet plans to expand its workforce from over 350 employees to approximately 1,000 in the coming years, representing a substantial investment of US$200mil by the end of 2026.